Reviews - 3wd5 mentioned but not cited (2)
- Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs. Shin WH, Kumazawa K, Imai K, Hirokawa T, Kihara D. Adv Appl Bioinform Chem 13 11-25 (2020)
- Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Lim H, Lee SH, Lee HT, Lee JU, Son JY, Shin W, Heo YS. Int J Mol Sci 19 (2018)
Articles - 3wd5 mentioned but not cited (29)
- Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, Guo Y, Lou Z. J. Biol. Chem. 288 27059-27067 (2013)
- A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. Choi DK, Bae J, Shin SM, Shin JY, Kim S, Kim YS. MAbs 6 1402-1414 (2014)
- Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Gaciarz A, Veijola J, Uchida Y, Saaranen MJ, Wang C, Hörkkö S, Ruddock LW. Microb. Cell Fact. 15 22 (2016)
- A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. Schröter C, Günther R, Rhiel L, Becker S, Toleikis L, Doerner A, Becker J, Schönemann A, Nasu D, Neuteboom B, Kolmar H, Hock B. MAbs 7 138-151 (2015)
- Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange. van Schie KA, Ooijevaar-de Heer P, Dijk L, Kruithof S, Wolbink G, Rispens T. Sci Rep 6 32747 (2016)
- An expanded benchmark for antibody-antigen docking and affinity prediction reveals insights into antibody recognition determinants. Guest JD, Vreven T, Zhou J, Moal I, Jeliazkov JR, Gray JJ, Weng Z, Pierce BG. Structure 29 606-621.e5 (2021)
- Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, van der Schoot CE, IJspeert H, van der Burg M, Gils A, Hafkenscheid L, Toes REM, Rombouts Y, Plomp R, Wuhrer M, van Ham SM, Vidarsson G, Rispens T. Proc. Natl. Acad. Sci. U.S.A. 115 1901-1906 (2018)
- Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy. Hu CW, Chang YC, Liu CH, Yu YA, Mou KY. Mol Ther 30 2522-2536 (2022)
- Higher order structures of Adalimumab, Infliximab and their complexes with TNFα revealed by electron microscopy. Tran BN, Chan SL, Ng C, Shi J, Correia I, Radziejewski C, Matsudaira P. Protein Sci. 26 2392-2398 (2017)
- Computational Design of an Allosteric Antibody Switch by Deletion and Rescue of a Complex Structural Constellation. Khowsathit J, Bazzoli A, Cheng H, Karanicolas J. ACS Cent Sci 6 390-403 (2020)
- Conformational ensemble of the TNF-derived peptide solnatide in solution. Martin-Malpartida P, Arrastia-Casado S, Farrera-Sinfreu J, Lucas R, Fischer H, Fischer B, Eaton DC, Tzotzos S, Macias MJ. Comput Struct Biotechnol J 20 2082-2090 (2022)
- Lipid-Based Nanoparticle Formulation of Diallyl Trisulfide Chemosensitizes the Growth Inhibitory Activity of Doxorubicin in Colorectal Cancer Model: A Novel In Vitro, In Vivo and In Silico Analysis. Alrumaihi F, Khan MA, Babiker AY, Alsaweed M, Azam F, Allemailem KS, Almatroudi AA, Ahamad SR, Alsugoor MH, Alharbi KN, Almansour NM, Khan A. Molecules 27 2192 (2022)
- Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study. Hong ST, Su YC, Wang YJ, Cheng TL, Wang YT. Biomolecules 11 334 (2021)
- Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Gjølberg TT, Frick R, Mester S, Foss S, Grevys A, Høydahl LS, Jørstad ØK, Schlothauer T, Sandlie I, Moe MC, Andersen JT. Commun Biol 5 832 (2022)
- Flash Oxidation (FOX) System: A Novel Laser-Free Fast Photochemical Oxidation Protein Footprinting Platform. Sharp JS, Chea EE, Misra SK, Orlando R, Popov M, Egan RW, Holman D, Weinberger SR. J Am Soc Mass Spectrom 32 1601-1609 (2021)
- Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. Andrick BJ, Schwab AI, Cauley B, O'Donnell LA, Meng WS. PLoS ONE 10 e0135451 (2015)
- The trimer to monomer transition of Tumor Necrosis Factor-Alpha is a dynamic process that is significantly altered by therapeutic antibodies. Daub H, Traxler L, Ismajli F, Groitl B, Itzen A, Rant U. Sci Rep 10 9265 (2020)
- Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. van de Bovenkamp FS, Derksen NIL, van Breemen MJ, de Taeye SW, Ooijevaar-de Heer P, Sanders RW, Rispens T. Front Immunol 9 740 (2018)
- A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Rusche H, Marrani E, Real-Fernandez F, Ponti R, Terzani F, Maccora I, Monasson O, Mastrolia MV, Peroni E, Pagnini I, Cimaz R, Papini AM, Simonini G, Rovero P. Sci Rep 11 16393 (2021)
- EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, Vecchi MM, Preyer M. MAbs 10 1248-1259 (2018)
- Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility. Saporiti S, Laurenzi T, Guerrini U, Coppa C, Palinsky W, Benigno G, Palazzolo L, Ben Mariem O, Montavoci L, Rossi M, Centola F, Eberini I. Commun Biol 6 237 (2023)
- Epitope Mapping with Diethylpyrocarbonate Covalent Labeling-Mass Spectrometry. Tremblay CY, Kirsch ZJ, Vachet RW. Anal Chem 94 1052-1059 (2022)
- Huoxue Qingre decoction used for treatment of coronary heart disease network analysis and metabolomic evaluation. Tan YQ, Jin M, He XH, Chen HW. Front Pharmacol 13 1025540 (2022)
- IgG1 conformational behavior: elucidation of the N-glycosylation role via molecular dynamics. Saporiti S, Parravicini C, Pergola C, Guerrini U, Rossi M, Centola F, Eberini I. Biophys J 120 5355-5370 (2021)
- Impact of Bioconjugation on Structure and Function of Antibodies for Use in Immunoassay by Hydrogen-Deuterium Exchange Mass Spectrometry. Luckau L, Groves K, Blencowe C, Scrimshaw S, Dent A, Quaglia M. Front Mol Biosci 9 866843 (2022)
- Impact of Qi-Invigorating Traditional Chinese Medicines on Diffuse Large B Cell Lymphoma Based on Network Pharmacology and Experimental Validation. Huang Q, Lin J, Huang S, Shen J. Front Pharmacol 12 787816 (2021)
- Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies-in silico analysis. Ahsan T, Sajib AA. J Genet Eng Biotechnol 20 7 (2022)
- Specific S100 Proteins Bind Tumor Necrosis Factor and Inhibit Its Activity. Kazakov AS, Zemskova MY, Rystsov GK, Vologzhannikova AA, Deryusheva EI, Rastrygina VA, Sokolov AS, Permyakova ME, Litus EA, Uversky VN, Permyakov EA, Permyakov SE. Int J Mol Sci 23 15956 (2022)
- Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. Eldirany SA, Ho M, Bunick CG. Yale J Biol Med 93 19-27 (2020)
Reviews citing this publication (7)
- Current approaches to fine mapping of antigen-antibody interactions. Abbott WM, Damschroder MM, Lowe DC. Immunology 142 526-535 (2014)
- New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Slevin SM, Egan LJ. Inflamm. Bowel Dis. 21 2909-2920 (2015)
- Tumor necrosis factor inhibitors in psoriatic arthritis. Mantravadi S, Ogdie A, Kraft WK. Expert Rev Clin Pharmacol 10 899-910 (2017)
- The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies. Sarodaya N, Karapurkar J, Kim KS, Hong SH, Ramakrishna S. Cancers (Basel) 12 (2020)
- Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, Fazlinejad R, Mohammadi-Samani S, Firouzabadi N, Hosseini M, Farjadian F. Future Microbiol 16 1415-1451 (2021)
- Pathogenesis and current therapies for non-infectious uveitis. Wu X, Tao M, Zhu L, Zhang T, Zhang M. Clin Exp Med (2022)
- Therapeutic drug monitoring for biological medications in inflammatory bowel disease. Cogan RC, El-Matary BW, El-Matary WM. Saudi J Gastroenterol 28 322-331 (2022)
Articles citing this publication (52)
- Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Lei C, Qian K, Li T, Zhang S, Fu W, Ding M, Hu S. Nat Commun 11 2070 (2020)
- Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. Nguyen DX, Ehrenstein MR. J. Exp. Med. 213 1241-1253 (2016)
- Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Science 351 1343-1346 (2016)
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, Ryu SE, Son JY, Lee JU, Heo YS. Nat Commun 7 13354 (2016)
- The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. Ann. Rheum. Dis. 74 311-314 (2015)
- Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies. Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, Xu Q, He L, Tan W, Bethune AN, Zhou L. MAbs 6 978-990 (2014)
- Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis. Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S. Eur J Health Econ 15 Suppl 1 S93-100 (2014)
- Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments. Krayukhina E, Noda M, Ishii K, Maruno T, Wakabayashi H, Tada M, Suzuki T, Ishii-Watabe A, Kato M, Uchiyama S. MAbs 9 664-679 (2017)
- A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays. Ni Y, Rosier BJHM, van Aalen EA, Hanckmann ETL, Biewenga L, Pistikou AM, Timmermans B, Vu C, Roos S, Arts R, Li W, de Greef TFA, van Borren MMGJ, van Kuppeveld FJM, Bosch BJ, Merkx M. Nat Commun 12 4586 (2021)
- Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Crit Care 24 331 (2020)
- LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. Zhang Y, Yang J, Wang J, Guo H, Jing N. Med. Oncol. 31 99 (2014)
- Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody. Yu X, Wang L, Shen Y, Wang C, Zhang Y, Meng Y, Yang Y, Liang B, Zhou B, Wang H, Wei H, Lei C, Hu S, Li B. Mol. Immunol. 87 300-307 (2017)
- LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. Liu J, Yan P, Jing N, Yang J. Tumour Biol. 35 8161-8167 (2014)
- Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma. Zhou F, Gou S, Xiong J, Wu H, Wang C, Liu T. Mol. Biol. Rep. 41 8163-8167 (2014)
- Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure. Chen K, Long DS, Lute SC, Levy MJ, Brorson KA, Keire DA. J Pharm Biomed Anal 128 398-407 (2016)
- Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Wang Y, Li H, Liang Q, Liu B, Mei X, Ma Y. Tumour Biol. 36 1561-1566 (2015)
- MAbTope: A Method for Improved Epitope Mapping. Bourquard T, Musnier A, Puard V, Tahir S, Ayoub MA, Jullian Y, Boulo T, Gallay N, Watier H, Bruneau G, Reiter E, Crépieux P, Poupon A. J Immunol 201 3096-3105 (2018)
- Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Lee JU, Shin W, Son JY, Yoo KY, Heo YS. Int J Mol Sci 18 (2017)
- Rational design of antirheumatic prodrugs specific for sites of inflammation. Onuoha SC, Ferrari M, Sblattero D, Pitzalis C. 67 2661-2672 (2015)
- Infliximab crystal structures reveal insights into self-association. Lerch TF, Sharpe P, Mayclin SJ, Edwards TE, Lee E, Conlon HD, Polleck S, Rouse JC, Luo Y, Zou Q. MAbs 9 874-883 (2017)
- Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues. Kaleli NE, Karadag M, Kalyoncu S. Proteins 87 607-618 (2019)
- Cell-free production and streamlined assay of cytosol-penetrating antibodies. Min SE, Lee KH, Park SW, Yoo TH, Oh CH, Park JH, Yang SY, Kim YS, Kim DM. Biotechnol. Bioeng. 113 2107-2112 (2016)
- Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Dohlman CH, Cade F, Regatieri CV, Zhou C, Lei F, Crnej A, Harissi-Dagher M, Robert MC, Papaliodis GN, Chen D, Aquavella JV, Akpek EK, Aldave AJ, Sippel KC, DʼAmico DJ, Dohlman JG, Fagerholm P, Wang L, Shen LQ, González-Andrades M, Chodosh J, Kenyon KR, Foster CS, Pineda R, Melki S, Colby KA, Ciolino JB, Vavvas DG, Kinoshita S, Dana R, Paschalis EI. Cornea 37 248-251 (2018)
- Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera. Homann A, Röckendorf N, Kromminga A, Frey A, Platts-Mills TA, Jappe U. Theranostics 7 4699-4709 (2017)
- In silico studies for the interaction of tumor necrosis factor-alpha (TNF-α) with different saponins from Vietnamese ginseng (Panax vietnamesis). Kim OT, Le MD, Trinh HX, Nong HV. Biophys Physicobiol 13 173-180 (2016)
- RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody. Hu S, Dai H, Zhang T, Fu W, Berezov SD, Chen C, Jorissen D, Takeda H, Bethune AN. Cancer Lett. 357 374-383 (2015)
- Self-Antigens Displayed on Liposomal Nanoparticles above a Threshold of Epitope Density Elicit Class-Switched Autoreactive Antibodies Independent of T Cell Help. Chen Z, Wholey WY, Hassani Najafabadi A, Moon JJ, Grigorova I, Chackerian B, Cheng W. J Immunol 204 335-347 (2020)
- Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis. Doki T, Toda M, Hasegawa N, Hohdatsu T, Takano T. Arch Virol 165 1197-1206 (2020)
- BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, Yoo KY, Ryu SE, Rhie J, Lee JY, Heo YS. Nat Commun 9 1200 (2018)
- Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T. Sci Transl Med 11 (2019)
- Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease. Kaji M, Kishi T, Miyamae T, Nagata S, Yamanaka H, Fujikawa S. Case Rep Rheumatol 2015 716138 (2015)
- Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis. Skougaard M, Ditlev SB, Stisen ZR, Coates LC, Ellegaard K, Kristensen LE. Arthritis Res Ther 24 262 (2022)
- IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design. Stoyle CL, Stephens PE, Humphreys DP, Heywood S, Cain K, Bulleid NJ. Biochem. J. 474 3179-3188 (2017)
- Case Reports Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis. Rivolta F, Sangalli A, Cappelletti C, Chiei Gallo A, Dubini M, Pravettoni V. Clin Case Rep 11 e7067 (2023)
- TNF-alpha inhibitor adalimumab attenuates endotoxin induced cardiac damage in rats. Durmaz S, Kurtoğlu T, Barbarus E, Eliyatkın N, Yılmaz M. Acta Cir Bras 35 e202000202 (2020)
- A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential. Luchese MD, Lopes Dos Santos M, Garbuio A, Targino RC, Mansueli CP, Tsuruta LR, Quintilio W, Moro AM. Immunol. Res. 66 392-405 (2018)
- An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. Ubah OC, Steven J, Porter AJ, Barelle CJ. Front Immunol 10 526 (2019)
- Characterization of Novel Fragment Antibodies Against TNF-alpha Isolated Using Phage Display Technique. Alizadeha AA, Hamzeh-Mivehroud M, Haddad E, Haddad N, Sharifi M, Mohammadi S, Pourtaghi-Anvarian S, Dastmalchi S. Iran J Pharm Res 18 759-771 (2019)
- Characterization of the novel anti-TNF-α single-chain fragment antibodies using experimental and computational approaches. Pourtaghi-Anvarian S, Mohammadi S, Hamzeh-Mivehroud M, Alizadeh AA, Dastmalchi S. Prep Biochem Biotechnol 49 38-47 (2019)
- Combining deep mutational scanning to heatmap of HLA class II binding of immunogenic sequences to preserve functionality and mitigate predicted immunogenicity. Sivelle C, Sierocki R, Lesparre Y, Lomet A, Quintilio W, Dubois S, Correia E, Moro AM, Maillère B, Nozach H. Front Immunol 14 1197919 (2023)
- Complementary Structural Information for Antibody-Antigen Complexes from Hydrogen-Deuterium Exchange and Covalent Labeling Mass Spectrometry. Tremblay CY, Kirsch ZJ, Vachet RW. J Am Soc Mass Spectrom 33 1303-1314 (2022)
- Case Reports Erythema Dyschromicum Perstans After Adalimumab Treatment. Alsisi GG, Alsisi MH, Alhowaish AK, Alshammari WS. Cureus 14 e32264 (2022)
- Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature. Park D, Yun J, Hwang SJ, Park SJ. Adv Ther 36 442-450 (2019)
- Expression, purification, crystallization and preliminary X-ray analysis of the HER3-9E12 Fab complex. He K, Huang A, Huang Y, Takeda H. Acta Crystallogr F Struct Biol Commun 70 786-789 (2014)
- Identification of HLA-DRB1 association to adalimumab immunogenicity. Liu M, Degner J, Davis JW, Idler KB, Nader A, Mostafa NM, Waring JF. PLoS ONE 13 e0195325 (2018)
- Membrane Protein Binding Interactions Studied in Live Cells via Diethylpyrocarbonate Covalent Labeling Mass Spectrometry. Kirsch ZJ, Blake JM, Huynh U, Agrohia DK, Tremblay CY, Graban EM, Vaughan RC, Vachet RW. Anal Chem 95 7178-7185 (2023)
- Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19. Sharma A. Cytokine 148 155719 (2021)
- Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab. Ono M, Horita S, Sato Y, Nomura Y, Iwata S, Nomura N. Protein Sci. 27 1038-1046 (2018)
- Structure-based development and optimization of therapy antibody drugs against TNFα. Fu W, Wang X, Yang W, Takeda H, Hu S, Lou Z, Zhao J, Bethune AN, Guo Y. Amino Acids 47 1259-1266 (2015)
- Testing the potency of anti-TNF-α and anti-IL-1β drugs using spheroid cultures of human osteoarthritic chondrocytes and donor-matched chondrogenically differentiated mesenchymal stem cells. Žigon-Branc S, Barlič A, Knežević M, Jeras M, Vunjak-Novakovic G. Biotechnol. Prog. 34 1045-1058 (2018)
- The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies. Gurjar SA, Wheeler JX, Wadhwa M, Thorpe R, Kimber I, Derrick JP, Dearman RJ, Metcalfe C. J. Biol. Chem. 294 19616-19634 (2019)
- Tumor Necrosis Factor-α Trimer Disassembly and Inactivation via Peptide-Small Molecule Synergy. Checco JW, Eddinger GA, Rettko NJ, Chartier AR, Gellman SH. ACS Chem Biol 15 2116-2124 (2020)